Pimelic Diphenylamide 106

Pimelic Diphenylamide 106 (TC-H 106) is a slow, tight binding class I HDAC inhibitor (inhibits HDAC1, 2, and 3 with IC50 values of 150 nM, 760 nM, and 370 nM, respectively), with no activity against class II HDACs. Pimelic Diphenylamide 106 modulates dopamine concentration and protects dopamine cells by inducing VMAT2 expression. Pimelic Diphenylamide 106 can be used in the study of neuropsychiatric diseases such as attention deficit hyperactivity disorder (ADHD) [1][2][3].

Product Specifications

CAS Number

[937039-45-7]

Product Name Alternative

RGFA-8; TC-H 106; Histone Deacetylase Inhibitor VII

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

HDAC; Monoamine Transporter

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; Membrane Transporter/Ion Channel

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Pimelic-Diphenylamide-106.html

Concentration

10mM

Purity

98.54

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(NC1=CC=CC=C1N)CCCCCC(NC2=CC=C(C)C=C2)=O

Molecular Formula

C20H25N3O2

Molecular Weight

339.43

Precautions

H302, H315, H319, H335

References & Citations

[1]Chou CJ, et al. Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases. J Biol Chem. 2008 Dec 19;283 (51) :35402-35409.|[2]Xu C, et al. Chemical probes identify a role for histone deacetylase 3 in Friedreich's ataxia gene silencing. Chem Biol. 2009 Sep 25;16 (9) :980-989.|[3]Lee, et al. "Dopaminergic cell protection and alleviation of neuropsychiatric disease symptoms by VMAT2 expression through the class I HDAC inhibitor TC‐H 106." Pharmacology Research & Perspectives 11.5 (2023) : e01135.